DARKPOOL0.1.0
AFT-MKT Sign in
ZBIO
Zenas BioPharma, Inc.
NMS Equity
28.70
+0.12 (+0.42%)
52w low 13.50 44.60 high
48.9% of range
Open
28.95
High
29.50
Low
28.50
Prev Close
28.58
Volume
306.26K
Avg Vol 3M
661.36K
Market Cap
1.95B
Currency
USD

6 Month Trend

full chart ›
— C-- Chg-- Gap-- Vol-- ×avg-- σ-- SMA20-- SMA50-- SMA200-- RSI-- SPY-- DD-- Bench-- Sig-- Hist-- hover · click to pin · ← → step · drag to zoom · shift-drag to measure
20.0025.0030.00May 26Jun 26Jul 26Aug 26Sep 26Nov 26
—Context
  • Move across the chart.

Company

SectorHealthcare
IndustryBiotechnology
CountryUnited States
Employees167
Website ↗

Performance

change over each horizon
1D +0.42%
5D +0.84%
1M +8.71%
3M -8.28%
6M +44.00%
YTD -20.96%
1Y -18.47%
2Y +34.93%
3Y --
5Y --
MAX +69.62%

Technical Rating

990 daily bars
Hold
3 bullish 2 bearish 1 neutral
SignalReading
+ Price vs 50-day average 28.70 vs 27.16
+ Price vs 200-day average 28.70 vs 28.55
− 50-day vs 200-day 27.16 vs 28.55
+ MACD histogram +0.129
− 3-month rate of change -11.2%
· RSI (14) 56.0 (neutral)

A mechanical summary of past prices only — six indicators, one vote each. It uses no fundamentals, no news and no knowledge of your circumstances, and the signals disagree by design. Not investment advice.

ML Prediction

990 daily bars
SELL
SignalReading
Predicted next close 28.41
Predicted change -1.01%
Trend DOWN
Support / Resistance 25.24 / 30.03
Track record none scored yet
  • model: -1.0%
  • downtrend confirmed

A mechanical fit to past prices, nothing more — no fundamentals, no news, no view of your circumstances. Historically close to a coin flip on direction (see the backtest). Not investment advice.

Valuation

P/E Trailing--
P/E Forward-5.95x
Price / Book9.16x
Price / Sales176.94x
EV / EBITDA-5.47x
EPS Trailing-10.08
Dividend Yield0.00%
Beta-0.86

Profitability

Gross Margin0.00%
Operating Margin-2,747.54%
Net Margin0.00%
Return on Equity-265.11%
Return on Assets-37.88%
Revenue Growth--
Debt / Equity1.42x
Current Ratio9.42x

Business

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Keys & commands

/focus the command box
AAPL Enteropen a ticker
apple Entersearch by company name (suggestions drop down as you type)
AAPL GPopen a ticker on a screen: DES, GP, FA
W PORT HZNwatchlist, portfolio, horizon
1–5DES, GP, W, FA, PORT for the current symbol
↑ ↓ Escmove through suggestions, close
?this reference

On a chart: hover for the readout, click to pin, drag to zoom, shift-drag to measure.